MedTrace Logo

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

NCT02398526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 363

Last updated 2021-11-02

No results posted yet for this study

Summary

This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life nuclear medicine practice setting. In addition, overall survival, time to next tumor treatment (TTNT), time to first symptomatic skeletal event (SSE), course of blood counts, and safety will be assessed.

Conditions

  • Castration-Resistant Prostatic Cancer

Interventions

DRUG

Radium-223 dichloride, (Xofigo, BAY88-8223)

Dosage and treatment duration according to the decision of the treating physician

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-19
Primary Completion
2020-05-20
Completion
2020-07-15

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02398526 on ClinicalTrials.gov